US Stem Cell Inc (USRM)

[Dragon Lady]

17 CENTS, another NEW ALL TIME LOW TODAY

That makes ANOTHER 52 week LOW, and also another all, all, all time LOW, established today for the common shares. Amazing to me.

0.17 / 0.19 (18000 x 5000)

Closed at 19 CENTS, but hit 17 CENTS inter-day, setting another new record all, all, all time low. Wow.

Split adjusted for the recent 1000 to 1 massive R/S reverse split, that's:

17 CENTS / 1000 = .00017 split corrected. TRIPLE ZEROS after the decimal.

http://us-stemcell.com/2015/11/u-s-stem-cell-inc-fka-bioheart-inc-receives-finra-approval-for-reverse-split-and-name-change/

That 1000 to 1 reverse split was on Nov 4th, 2015 and the common shares are still in mass decline since then.



That's the YEAR TO DATE CHART FOR JUST 2016, and it shows massive common share price decline. Charts don't lie and have no bias- it's just visualized mathematics.

Start of Jan 2016, the common shares were trading at approx. 80 CENTS each.

Less than 3 months later, today, March 21st, the common shares put in a new 52 week and a new record all time LOW of 17 CENTS.

80 cents - 17 cents = 63 cents / 80 cents = 0.787 X 100 = 78.7% LOSS in less than 3 months.

The common shares are losing on average, approx 25% PER MONTH.

That's on top of the long term trend of already having lost 98% or more of their value.

Wow, stunning IMO. Staggering losses to the common shares and market cap. All IMO, due to un-ending using of common share dilution, primarily via un-ending use of convertible debt financing deals (see any recent SEC filed 10-K or 10-Q and see Magna Equities LLC, Fourth Man, Daniel James, Vis Vires group, KBM Worldwide, etc)

The incredible rate of common share dilution can be easily illustrated by comparing the O/S (outstanding share counts) per their last SEC filed 10-Q as compared to their most recent filed SEC 10-K:

http://www.sec.gov/Archives/edgar/data/1388319/000118518515002777/bioheart10q093015.htm

"As of November 05, 2015, there were 1,283,757 outstanding shares of the Registrant’s common stock, par value $0.001 per share. "


http://www.sec.gov/Archives/edgar/data/1388319/000118518516003859/usstemcell10k123115.htm

"The number of shares outstanding of the registrant’s Common Stock, $0.001 par value, as of March 8th, 2016 was 2,470,400."


That means in a period of ONLY approx 4 SHORT MONTHS, from Nov 5th, 2015 to March 8th, 2016 - the common shares outstanding essentially DOUBLED (just a tad shy of a doubling).

Split corrected for the recent 1000 to 1 reverse split, those 2,470,000 shares O/S = 1000X that or approx 2.4 BILLION shares of common issued since the company went public in 2008. A large percentage of the U.S. market's S&P 500 index member companies (some of the most profitable and successful companies to ever exist) never reach even 1 BILLION shares outstanding, let alone 2 BILLION plus shares outstanding.

Staggering dilution IMO, as the share price has been for all intents and purposes a straight down decline, the entire time, as shown in this long term chart of the common share price- from inception to today:



There it is. The visualized MATHEMATICAL FACTS as to the common share price declines- from the day Bioheart, now known as U.S. Stem Cell went public in early 2008, then was delisted from the Nasdaq in early 2009 to trade on the OTC markets, to 8 years later, to today, March 21 2016, when the common shares just made ANOTHER, RECORD, ALL, ALL, ALL TIME LOW by reaching 17 CENTS (aka .00017 split corrected) intra-day.

Charts don't lie and they have no bias. They're simply visual representations of mathematical data. One of the oldest, most utilized tools in existence- to "visualize" numbers. The chart or graph. Those charts above show what's essentially an un-broken line/trend of DECLINE to the common share price, heading clear back to the company's IPO in 2008, 8 years ago.

http://venturebeat.com/2008/02/20/bioheart-a-new-record-for-ipo-futility/

(Some journalistic commentary on the Bioheart IPO back in 2008. One can see even back then how rapidly their common share price collapsed and declined- so much, that they were delisted from the Nasdaq only approx 1 short year later in 2009, relegated to the OTC "penny" stock marketplace)

http://venturebeat.com/2008/02/19/three-yards-and-a-cloud-of-dust-bioheart-makes-it-across-the-ipo-goal-line-but-with-little-to-show-for-its-struggles/

https://globenewswire.com/news-release/2009/02/26/393349/160467/en/Bioheart-Inc-Receives-Notice-of-Delisting-From-The-NASDAQ-Capital-Market.html

http://www.bizjournals.com/southflorida/stories/2010/07/26/daily1.html

Simple as that, in my opinion. The graph. The chart. It's all there to me.